A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Clinical trial NCT04444167 · COMPLETED

Trial details

NCT number: NCT04444167
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2020-07-07
Primary completion: 2023-11-20
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.